We had pleasure to participate at Microbiome Connect USA in Boston. A two-day event, opening November 16, was a great opportunity to discuss about the importance of bacteriophages in microbiome.…
Phage Consultants was part of Pomorskie Region of Poland team in the Integrated Pharma (ICSE) Zone at CPhI in Frankfurt. We are very happy that we could talk about our…
At the end of October we had pleasure to participate at Microbiome R&D & Business Collaboration Forum in Miami. This conference was an opportunity to present our newly expanded service…
Phage Consultants will be exhibiting at CPhI Worldwide 2021 in Milan as part of the Pomorskie Region of Poland team in the Integrated Pharma (ICSE) Zone, at Booth 11H54. Visit us to find out more about our newest offer!
We will exhibit our bacteriophage detection technologies at DUPHAT from Booth 4C20, as part of the Pomeranian Region of Poland stand that showcases the most promising pharmaceutical and biotech companies of the region.
Producing bacteriophages is not easy, but Phage Consultants has you covered. We receive client samples contaminated with unknown bacteriophages on a daily basis, and often, in order to characterize the contaminant and subsequently remove it and prevent its reappearance, isolation of a bacteriophage and its production are required.
Phage Consultants will attend the upcoming online ISBioTech Waterside conference, with our CEO Dr. Marcin Los delivering an invited speaker talk: Crouching T1, Hidden DE3 – how lysogeny, pseudolysogeny and hibernation may camouflage phages in the process.
Given the COVID-19-related travelling restrictions, including recent closure of Japan to European visitors, PC was forced to reluctantly withdraw our registration for the next month’s INTERPHEX Week Tokyo meeting.
As the interest in bacteriophage-based technologies as an alternative to antibiotics in fighting microbial infections rises, Phage Consultants presents a short guide to phage testing and phage therapy and their potential medical uses.
In a recently published study, PC has contributed its bacteriophage expertise to promising research highlighting potential use of phage proteins as building blocks for nanoscale protein materials, which can in turn be used as drug or vaccine carriers of clinical importance.